Summit Therapeutics Inc [NASDAQ: SMMT] stock went on an upward path that rose over 55.99% on Monday, amounting to a one-week price increase of more than 47.46%.
Over the last 12 months, SMMT stock rose by 1142.86%. The one-year Summit Therapeutics Inc stock forecast points to a potential upside of 22.42. The average equity rating for SMMT stock is currently 1.00, trading closer to a bullish pattern in the stock market.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for the stock reached $13.86 billion, with 701.66 million shares outstanding and 85.87 million shares in the current float. Compared to the average trading volume of 2.19M shares, SMMT stock reached a trading volume of 47647928 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Summit Therapeutics Inc [SMMT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SMMT shares is $24.67 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SMMT stock is a recommendation set at 1.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for Summit Therapeutics Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 12, 2024. While these analysts kept the previous recommendation, Citigroup raised their target price to Buy. The new note on the price target was released on May 07, 2024, representing the official price target for Summit Therapeutics Inc stock. Previously, the target price had yet another raise to $8, while Stifel analysts kept a Buy rating on SMMT stock.
The Average True Range (ATR) for Summit Therapeutics Inc is set at 1.51 The Price to Book ratio for the last quarter was 71.07, with the Price to Cash per share for the same quarter was set at 0.45.
SMMT Stock Performance Analysis:
Summit Therapeutics Inc [SMMT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 47.46. With this latest performance, SMMT shares gained by 86.91% in over the last four-week period, additionally plugging by 335.00% over the last 6 months – not to mention a rise of 1142.86% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SMMT stock in for the last two-week period is set at 80.95, with the RSI for the last a single of trading hit 84.79, and the three-weeks RSI is set at 77.61 for Summit Therapeutics Inc [SMMT]. The present Moving Average for the last 50 days of trading for this stock 10.72, while it was recorded at 13.70 for the last single week of trading, and 5.87 for the last 200 days.
Insight into Summit Therapeutics Inc Fundamentals:
Summit Therapeutics Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.35 and a Current Ratio set at 2.35.
SMMT Stock EPS
With the latest financial reports released by the company, Summit Therapeutics Inc posted -0.06/share EPS, while the average EPS was predicted by analysts to be reported at -0.06/share. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for SMMT.
Summit Therapeutics Inc [SMMT] Institutonal Ownership Details
There are presently around $10.49%, or 88.47%% of SMMT stock, in the hands of institutional investors. The top three institutional holders of SMMT stocks are: BAKER BROS. ADVISORS LP with ownership of 23.22 million shares, which is approximately 3.309%. VANGUARD GROUP INC, holding 8.82 million shares of the stock with an approximate value of $$68.78 million in SMMT stocks shares; and VANGUARD GROUP INC, currently with $$61.61 million in SMMT stock with ownership which is approximately 1.1255%.
